The decline in the U.S. contrast agents market is likely to last until 2017, according to this article. Companies expected to be affected include GE Healthcare, Mallinckrodt and Lantheus Medical Imaging. However, analyst Ravindra Sharma said the radiopharmaceuticals sector is a promising area. Another trend in the field is advancement not just in the chemical composition of contrast agents but in how they are administered, such as in the use of software to allow for integration of injectors, PACS and imaging devices.
Published in Brief: